|Bid||3.3200 x 800|
|Ask||3.3800 x 800|
|Day's Range||3.2700 - 3.4400|
|52 Week Range||3.0200 - 6.3000|
|Beta (3Y Monthly)||2.10|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
Inovio Pharmaceuticals' (INO) earnings and revenues disappoint with an estimate miss in the first quarter. Shares slip in after-hours trading.
More revenue, more cash, lower expenses, and a lot of pipeline activity were the major stories for the biotech in Q1.
Inovio (INO) delivered earnings and revenue surprises of -3.45% and -36.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Plymouth Meeting, Pennsylvania-based company said it had a loss of 30 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.
Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.
Inovio (INO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While many biopharmaceutical companies have partnerships or collaborations with one or two larger companies, Inovio Pharmaceuticals has product development deals in place with more than a half dozen pharmaceutical and biotech firms and research organizations inside and outside the United States. Inovio is in that position largely because it is developing a technology platform with two parts that can be applied to a variety of medical conditions. The second part is the system for delivering the therapy through the skin or into muscle tissues using brief and low voltage electronic pulses. That standing, said Inovio co-founder and CEO J. Joseph Kim, gives the Plymouth Meeting-based company different aspirations than other development-stage drug developers.
In a recent press release, Inovio (INO) said they completed enrollment three months ahead of schedule in the Phase 1/2, 52-patient trial of INO-5401 for newly-diagnosed glioblastoma, asserts Michael Murphy, growth stock expert and editor of New World Investor.
Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you own shares in Inovio Pharmaceuticals, Inc. (NASDAQ:INO) then it's worth thinking about how it contributes to the volat...
Inovio (INO) receives the third milestone payment from AstraZeneca post the initiation of dosing in a phase II combo study of the latter's MEDI0457 for HPV related anal, penile and vulvar cancers.
Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.
Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.
Shares of Inovio Pharmaceuticals Inc. rose 9% in premarket trade Thursday after the company announced that its investigational Ebola vaccine was able to elicit a strong antibody response in the majority of subjects in a Phase 1 trial. The vaccine, dubbed INO-4201, was given to 70 subjects either through a skin injection or an injection into muscle. Of those subjects, 67 were able to mount a strong antibody response to an Ebola antigen after three doses, while 52 were able to do so after only two doses, the company said. Inovio noted that the 13 subjects who received the vaccine through a skin injection were all able to mount an antigen-specific antibody response after just two doses. The vaccine, which is non-live as opposed to other investigational Ebola vaccines based on viral vectors, has not shown any serious systemic adverse effects like fever, joint pain or low white blood cell count, the company said. Shares of Inovio have fallen 10% in the year to date, while the S&P 500 has gained 12.7%.
Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.